In the meantime, H.C. Wainwright reiterated its Microbot Medical Inc [MBOT] rating to a Buy in a research note published on January 13, 2020; the price target was $26. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late December has reiterated a ‘”a Buy”‘ rating for it. Ladenburg Thalmann began covering MBOT with “Buy” recommendation on January 31, 2018.
Price Performance Review of MBOT
On Tuesday, Microbot Medical Inc [NASDAQ:MBOT] saw its stock fall -0.35% to $2.83. Over the last five days, the stock has gained 139.83%. Microbot Medical Inc shares have risen nearly 152.68% since the year began. Nevertheless, the stocks have risen 105.07% over the past one year. While a 52-week high of $3.38 was reached on 01/06/25, a 52-week low of $0.82 was recorded on 01/02/25. SMA at 50 days reached $1.08, while 200 days put it at $1.02.
Levels Of Support And Resistance For MBOT Stock
The 24-hour chart illustrates a support level at 2.48, which if violated will result in even more drops to 2.12. On the upside, there is a resistance level at 3.09. A further resistance level may holdings at 3.34. The Relative Strength Index (RSI) on the 14-day chart is 93.91, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.23, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 22.45%. Stochastics %K at 82.39% indicates the stock is a selling.
How much short interest is there in Microbot Medical Inc?
A steep rise in short interest was recorded in Microbot Medical Inc stocks on 2024-10-31, growing by 0.25 million shares to a total of 0.57 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.32 million shares. There was a rise of 43.62%, which implies that there is a positive sentiment for the stock.
